Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey

BACKGROUND: Cyproterone acetate 2 mg/ethinylestradiol 35 µg, an estrogen/progestogen treatment with anti-androgenic properties, shares a thromboembolism risk with combined hormonal contraceptives. Educational materials (i.e., direct healthcare professional communication, patient information card, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Kimberly H., Asiimwe, Alex, Zografos, Laurie J., McSorley, David J., Andrews, Elizabeth B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629244/
https://www.ncbi.nlm.nih.gov/pubmed/29056853
http://dx.doi.org/10.1007/s40290-017-0203-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629244/
https://www.ncbi.nlm.nih.gov/pubmed/29056853
http://dx.doi.org/10.1007/s40290-017-0203-9

Ejemplares similares